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Elevated numbers of PD-L1 
expressing B cells are associated 
with the development of AIDs-NHL
Marta epeldegui1,2,3, David V. Conti4, Yu Guo3, Wendy Cozen4,5, Manuel L. penichet1,2,6,7,8 & 
otoniel Martínez-Maza1,2,3,7,9
The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human 
immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy 
(cART). Both the loss of immunoregulation of Epstein-Barr virus (EBV) infected cells, as well as chronic 
B-cell activation, are believed to contribute to the genesis of AIDS-related NHL (AIDS-NHL). However, 
the mechanisms that lead to AIDS-NHL have not been completely defined. A subset of B cells that is 
characterized by the secretion of IL10, as well as the expression of the programmed cell death ligand-1 
(PD-L1/CD274), was recently described. These PD-L1+ B cells can exert regulatory function, including 
the dampening of T-cell activation, by interacting with the program cell death protein (PD1) on target 
cells. The role of PD-L1+ B cells in the development of AIDS-NHL has not been explored. We assessed 
B cell PD-L1 expression on B cells preceding AIDS-NHL diagnosis in a nested case-control study of 
HIV+ subjects who went on to develop AIDS-NHL, as well as HIV+ subjects who did not, using multi-
color flow cytometry. Archival frozen viable PBMC were obtained from the UCLA Multicenter AIDS 
Cohort Study (MACS). It was seen that the number of CD19+CD24++CD38++and CD19+PD-L1+cells was 
significantly elevated in cases 1–4 years prior to AIDS-NHL diagnosis, compared to controls, raising 
the possibility that these cells may play a role in the etiology of AIDS-NHL. Interestingly, most PD-L1+ 
expression on CD19+ cells was seen on CD19+CD24++CD38++ cells. In addition, we showed that HIV can 
directly induce PD-L1 expression on B cells through interaction of virion-associated CD40L with CD40 on 
B cells.
AIDS-NHL, comprising Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), primary effusion lym-
phoma, and primary central nervous system lymphoma (PCNSL), are the most common cancers seen in per-
sons living with HIV in the United States and other countries with widespread access to effective combination 
anti-retroviral therapy (cART)1. While, the incidence of AIDS, and AIDS-NHL, has decreased in the cART era, 
NHL remains a significant clinical problem, causing 23–30% of AIDS-related deaths in countries in which per-
sons living with HIV infection have access to cART2–4.
Chronic B cell activation associated with HIV infection, as well as the loss of immunoregulation of 
Epstein-Barr virus (EBV) infected B cells, are believed to contribute to the development of NHL5–7. Epidemiologic 
evidence points to a potential role for immune stimulatory molecules in the etiology of AIDS-NHL, as elevated 
levels of several of these molecules (IL6, IL10, BCA1/CXCL13, IP10/CXCL10, MCP1, TARC/CCL17, TNFα, 
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BAFF, IL18, sCD14, sCD163, sCD23, sCD27, sCD30, neopterin, κ and λ immunoglobulin free light chains [FLC]) 
were observed to precede the development of AIDS-NHL8–15. Additionally, in vitro studies show that certain 
cytokines induce the expression and activity of activation-induced cytidine deaminase (AICDA) in B cells16. 
AICDA mediates somatic hypermutation (SHM) and double-strand DNA recombination associated with IgH 
class switch recombination (CSR)17. AICDA expression/activity also can result in lymphomagenic lesions by 
inducing oncogene mutation/translocation18–22. We and others have shown that HIV virions can directly activate 
B cells and induce AICDA expression, via host cell-produced stimulatory molecules that are incorporated into 
HIV, such as CD40 ligand (CD40L)23,24. These studies provide strong evidence that B cell activation precedes and 
may contribute to the development of AIDS-NHL.
A population of B cells with regulatory function, which have been termed regulatory B cells (Bregs), has been 
recognized25. Bregs are analogous to regulatory T cells, or Tregs, which are T cells that can dampen adaptive 
immune responses via the secretion of inhibitory cytokines, such as IL10 and TGFβ. Bregs require the interaction 
of CD40L and CD40, expressed on T and B cells, respectively, to function25. This Breg population can dampen T 
cell function, mainly by producing and secreting IL10 and TGFβ, in a manner analogous to that of Treg cells25.
In prior work, we observed that serum IL10 levels are elevated over a period of years (1–5 years) preceding 
AIDS-NHL diagnosis9,13,26,27, as well as after AIDS-NHL diagnosis28. Additionally, an IL10 genotype that is asso-
ciated with enhanced IL10 production was seen to be a risk factor for AIDS-NHL27. Others have described the 
important role of IL10 in the modulation of T-cell function in HIV infection29. It recently was shown that HIV+ 
persons, even those who are on cART, display high levels of IL10 expressing B cells30, and Breg cells from HIV+ 
individuals can suppress CD8 function in an IL10-dependent manner30. We showed that exposure of resting B 
cells from HIV-negative donors to HIV virions containing CD40L led to the secretion of high levels of IL10 by 
these virion-stimulated cells, in addition to AICDA expression23. Therefore, HIV appears to have the potential to 
induce the generation of Breg cells.
A small (n = 12) study by Siewe et al. showed that Breg cell numbers appeared to be elevated prior to 
AIDS-NHL31. It has been previously shown that Toll-like receptor (TLR) activated Breg cells up-regulate the 
programed death-ligand-1 (PD-L1/CD274)30, and additionally, that Breg cells can inhibit CD4+ T cells through 
both IL10 and PD-L132. Therefore, expression of PD-L1 on B cells may provide additional pathway, in addition to 
IL10, for Breg cells to inhibit T cell function.
Here we show that numbers of both Breg cells (CD19+CD24++CD38++ cells) and CD19+PD-L1+ cells 
were elevated in the peripheral circulation of HIV+ subjects prior to AIDS-NHL diagnosis, when compared 
to the levels seen in HIV+ controls who did not develop AIDS-NHL. Moreover, the majority (~80%) of these 
CD19+PD-L1+ cells were Breg cells. The presence of such Breg cells raises the possibility that these cells may 
inhibit T cell function in a dual fashion, through the actions of both IL10 and PD-L1, thereby contributing to 
lymphomagenesis. We also show that HIV can diretly induce PD-L1 expression on B cells.
Results
Study population. Cases and controls were similar in their distributions by recruitment year, CD4+ T cell 
count, and antiretroviral drug therapy, as expected based on the matched design (Table 1). The majority of con-
trols and cases were non-Hispanic whites (65.5% and 89.0% respectively). Cases and controls were matched by 
age with a mean age of 33 years for both groups. Cases and controls had relatively high levels of CD4+ T cells, 
with a mean of 464 and 533 CD4+ T cells/mm3 in controls and cases, respectively. The majority were antiret-
roviral drug naïve (100% of controls and 95% of cases). All AIDS-NHL cases had systemic lymphoma, equally 
distributed between DLBCL and BL. The HIV-negative group was 100% male, with a mean age of 38 ± 9 years 
and mean CD4+ T cells/mm3 of 975 ± 168. The majority of the HIV-negative controls were white non-Hispanic 
and Hispanic (66.5% and 28% respectively).
Bregs (CD19+CD24++CD38++) are elevated prior to AIDS-NHL diagnosis. We stained PBMC 
from HIV+ cases and matched HIV+ controls with antibodies that characterize the Breg cell phenotype 
(CD19+CD24++CD38++), and assessed these cells using multi-parameter flow cytometry. We observed 
that PBMC Breg cells were significantly elevated in AIDS-NHL cases 1–4 years prior to their NHL diagnosis 
(p = 0.003), when compared to their HIV+ matched controls (Fig. 1A). However, Breg cells were not significantly 
elevated in the circulation of HIV+ NHL cases >4 years prior to diagnosis, when compared to their HIV+ 
matched controls. PBMC collected from AIDS-NHL cases 1–4 years prior to NHL diagnosis had significantly 
higher numbers of Breg cells compared to those collected (in the same individuals) > 4 years prior to diagnosis 
(p = 0.045). However, there was no significant difference in Breg numbers across visits in the HIV+ matched 
controls (Fig. 1B,C). Lastly, we did observe differences in numbers of Breg cells when we compared the HIV+ and 
HIV-negative control groups (p = 0.025), suggesting that HIV infection plays a role in increased numbers of Breg 
cells (Fig. 1A); however, individuals who went on to develop AIDS-NHL displayed even higher levels of Breg cells.
CD19+PD-L1+ are elevated prior to AIDS-NHL diagnosis. Recent reports indicate that B cells that 
express PD-L1 on their surface can impair/inhibit T cell function32. To define PD-L1 expression on B cells, we 
stained PBMC with anti-CD19 and anti-PD-L1, and assessed these cells by flow cytometry, finding a significant 
increase in the number of PD-L1+ B cells in the circulation of AIDS-NHL cases 1–4 years, but not >4 years, 
prior to NHL diagnosis (p = 0.029) (Fig. 2A). PD-L1 expression on B cells was elevated in all HIV+ subjects, 
regardless of case status, compared to HIV-negative controls (p = 0.005 and p = 0.01), suggesting that HIV infec-
tion is associated with PD-L1 expression on B cells (Fig. 2A). Moreover, we observed that the levels of PD-L1+ 
B cells increased closer to AIDS-NHL diagnosis, compared to the levels of these cells detected at an earlier time 
(p = 0.013) (Fig. 2B,C).
3Scientific RepoRts | (2019) 9:9371 | https://doi.org/10.1038/s41598-019-45479-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Breg cells (CD19+CD24++CD38++) were more elevated in those who developed DLBCL. We 
observed that Breg cells were significantly more elevated 1–4 years before diganosis in those HIV+ subjects who 
went on to develop AIDS-NHL of the DLBCL subtype, when compared to subjects who developed AIDS-NHL 
of the BL subtype (p = 0.003) (Fig. 3). In contrast, we did not see any significant difference in the numbers of 
CD19+PD-L1+ cells in those HIV+ persons who went on to develop DLBCL or BL (data not shown).
CD19+PD-L1+ B cells appear to be a subpopulation of Breg cells. Others have noted that Breg cells 
can express PD-L130. Therefore, we further characterized the phenotype of B cells that express PD-L1 prior to 
AIDS-NHL diagnosis. To do this, we utilized multicolor flow cytometry to further characterize CD19+PD-L1+ 
cells. We observed that the majority of the PD-L1+ B cells had a phenotype consistent with that of Breg cells 
(CD19+CD24++CD38++), indicating that these PD-L1+ B cells are a subpopulation of the so-called Breg cell 
population, at least in these HIV+ subjects who went on to develop AIDS-NHL (Fig. 4).
CD40L-containing HIV induces PD-L1 on B cells. CD40 activation is known to lead to Breg cell devel-
opment25. In prior work, we23,24 and others23,24 found that HIV virions, produced in human T cells, contain 
CD40L, presumably obtained after lytic infection of these infected host cells. Therefore, we determined whether 
exposure of B cells to HIV virions up-regulated PD-L1 expression. We stimulated B cells isolated from the periph-
eral blood of healthy donors with HIV virions that express CD40L on their surface (CD40L+ HIV virions), find-
ing that PD-L1 expression was increased significantly (p = 0.032). In contrast, B cells that were exposed to HIV 
virions that expressed a non-functional, mutant form of CD40L (T147N-HIV) were not stimulated to express 
PD-L1 (Fig. 5A). Therefore, CD40L+ HIV virions can directly induce PD-L1 expression on B cells, providing a 
mechanism for how PD-L1 expression may be driven on these cells by HIV infection. We also measured levels of 
IL10 in the supernatants collected from B cells exposed to CD40L+ HIV. B cells stimulated with CD40L+ HIV 
virions were seen to secrete IL10, in addition to expressing PD-L1, indicating that these B cells have the potential 
to function as Breg cells via both IL10 secretion and PD-L1 expression (Fig. 5B).
Discussion
Chronic B-cell activation is believed to play an important role in HIV infection-associated immune dysfunction, 
as well as in the development of AIDS-NHL. However, the mechanisms by which B-cell activation and dysfunction 
contribute to AIDS-NHL have not been fully defined. Here we show that Breg cells (CD19+CD24++CD38++), as 
well as B cells expressing PD-L1 (CD19+PD-L1+ cells), are elevated prior to AIDS-NHL diagnosis. Additionally, 
we note significant overlap in these B cell subsets, as many Bregs were seen to also express PD-L1. These B cell 
subsets have the potential to play an important role in lymphomagenesis in a dual fashion, by enhancing B-cell 
activation (through IL10), and by impairing/inhibiting T cell function (through IL10 and PD-L1), including 
that of cytotoxic T cells (CTL), which may be involved in the immunoregulation of EBV infected B cells and/or 
HIV-infected CD4 T cells.
HIV-infected controls AIDS-NHL cases
n = 18 n = 18
age, median ± SD 33 ± 5 33 ± 4.9
sex
   male 100% 100%
   female 0% 0%
CD4, median ± SD 464 ± 216 533 ± 422
median months prior to NHL 
(visit) n/a 73.5 ± 26.4
HAART
   yes 0% 5%
   no 100% 95%
race
   white, non-Hispanic 66.5% 89.0%
   black, non-Hispanic 5.5% 0.0%
   Hispanic 28.0% 5.5%
   other 5.5%
tumor EBV status
   negative n/a 33%
   positive n/a 33%
   unknown n/a 33%
tumor subtype
   BL 50%
   DLBCL 50%
Table 1. Select characteristics of the study population. *Values for each participant at the PBMC sample 
date > 4 years prior to AIDS-NHL diagnosis. SD: standard deviation.
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It was previously shown by Siewe et al. that Breg cells are elevated prior to AIDS-NHL diagnosis31. However 
this initial study was limited by the small sample size (n = 12) and the proximity of the single sample collection 
to AIDS-NHL diagnosis (8 months prior to AIDS-NHL). In this larger study, we confirm that Breg cells are sig-
nificantly elevated in HIV infection, and are even more elevated prior to AIDS-NHL. We also quantified these 
Breg subsets over a longer time period preceding NHL diagnosis, as well as at two time periods preceding NHL 
diagnosis. We found that Breg cells were elevated prior to AIDS-NHL diagnosis and observed that Breg cells were 
elevated up to, but not beyond, 4 years prior to AIDS-NHL, when compared to HIV+ controls. However, Breg 
cells were significantly elevated 1–4 years prior to AIDS-NHL diagnosis when compared to Bregs from more than 
4 years prior to AIDS-NHL diagnosis in the same individual, suggesting that levels of Bregs increase approaching 
AIDS-NHL diagnosis. These observations suggest that elevated numbers of Breg cells in the peripheral blood 
of HIV+ subjects is a characteristic of subjects who develop AIDS-NHL, and that Breg cells may be involved 
in the pathogenesis of these cancers. We also observed significantly higher numbers of Breg cells in those who 
developed DLBCL, compared to those who developed BL. However this finding is tempered by the relatively low 
number of cases studied, due to stratification by AIDS-NHL subtype.
It has been shown that Breg cells from HIV+ subjects are able to inhibit CTL HIV-specific responses in a dual 
fashion, by secreting the T cell inhibitory cytokine IL10 and via ligation of PD1 on T cells by PD-L1 on B cells32. 
Here we show, as others have recently shown33, that higher numbers of B cells expressing PD-L1 are present in the 
peripheral blood of HIV infected individuals. Additionally, we show that HIV+ subjects who went on to develop 
AIDS-NHL have even higher numbers of CD19+PD-L1+ B cells, when compared to HIV+ controls in periph-
eral blood. PD-L1 is an immunomodulator, and is of great importance, since exhausted non-functional T cells 
express PD1 in HIV infection. The higher expression of PD-L1 on B cells in HIV infection raises the possibility 
Figure 1. Bregs were elevated prior to AIDS-NHL. (A) Multi-color flow cytometry for Breg cell phenotype 
(CD19+CD24++CD38++) was performed on prospectively collected PBMC from AIDS-NHL cases and 
matched HIV+ and HIV-negative controls. Breg cells were gated as CD19+CD24++CD38++; absolute numbers 
of Breg cells (cells/mm3) were measured 1–4 years and >4 years prior to AIDS-NHL diagnosis. Lines in 
represent means. (B,C) Absolute numbers of Breg cells in PBMC from HIV+ controls are shown at the two 
different visits; lines represent each individual changes across visits; lines represent each individual changes 
across visits. p-values were calculated using either an F-test or t-test for the difference in log means in a linear 
mixed model, respectively.
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that these CD19+PD-L1+ B cells may be interacting with T cells through PD1, contributing to the development 
of AIDS-NHL by inhibiting/impairing CD4+ and CD8+ T cells, which play an important role in dampening the 
growth of EBV-infected B cells and which can effect anti-tumor responses (Fig. 5).
Additionally, we show that exposure to HIV virions expressing CD40 ligand can modestly induce the expres-
sion of PD-L1 on B cells, as well as IL10 secretion. Lopez-Avente et al. recently showed that HIV can directly 
induce a regulatory B cell-like immunosuppressive phenotype (CD19+CD24++CD38++)34. Here, we extend their 
observations by showing that HIV may be inducing PD-L1 in this Breg cell phenotype, at least in part, through the 
expression of CD40L on HIV virions, which can interact with CD40 on B cells. This provides one mechanism by 
which PD-L1+ Breg cells may arise in HIV infection. It is important to note that AIDS-NHL tumor cells express 
PD-L135. The expression of PD-L1 on tumor cells can allow such cells to evade immune surveillance36. Together, 
these findings lead us to speculate that the induction of PD-L1 on B cells may be an early event driving lympho-
magenesis. Certainly, more work needs to be done to elucidate the role of PD-L1+ B cells in lymphomagenesis.
Methods
Study design and population. The study design is a nested case-control study within the Multicenter 
AIDS Cohort Study (MACS) cohort. The MACS is a prospective cohort study of the natural and treated history 
of HIV infection and AIDS37. We obtained 35 viable frozen peripheral blood mononuclear cells (PBMC) from 
individuals who developed NHL, collected prior to their NHL diagnosis (cases), from the UCLA MACS reposi-
tory. We studied samples from the same individual collected at two different MACS study visits: one at >4 years, 
and another at 1–4 years prior to NHL diagnosis (n = 18). For inidividuals (n = 11) who did not have two serial 
A)
B) C)
pre-NHL
HIV+ 
HIV-negative
p=0.005
p=0.01
p=0.029
HIV+
p=0.013
pre-NHL
Figure 2. CD19+PD-L1+ cells were elevated prior to AIDS-NHL diagnosis. (A) Multi-color flow cytometry was 
performed in prospectively collected PBMC from AIDS-NHL cases, as well as from matched HIV+ controls 
who did not develop NHL and from HIV-negative controls. Absolute numbers of CD19+PD-L1+ (cells/mm3) 
were measured 1–4 years before AIDS-NHL and >4 years prior to AIDS-NHL. (B,C) Absolute numbers of 
CD19+PD-L1+ cells in PBMC from HIV+ controls are shown at the two different visits; lines represent each 
individual changes across visits; lines represent each individual changes across. p-values were calculated using 
either an F-test or t-test for the difference in log means in a linear mixed model, respectively.
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samples, we used the one sample that was available in the analysis. We also obtained similar samples from 29 
HIV+ patients who did not develop NHL (HIV+ controls), matched to cases by date of birth (within 200 days), 
study visit (within 250 days) and CD4 count (±175cells/mm3), plus samples from an additional 15 HIV-negative 
controls obtained from the MACS, matched on study visit. The MACS was approved by the human subjects 
research review committees at all participating institutions; all human subjects participating in the MACS pro-
vided written informed consent. The specimens and clinical information provided by the MACS were stripped of 
any personal identifying information.
Flow cytometry. Multicolor flow cytometry was performed on 1 × 106 PBMC, for the following immune 
markers: CD3, CD4, CD19, CD24, CD38, CD71, CD1d, PD-L1 (eBioscience) and CD10 (Becton Dickenson, 
BD). These antibodies were conjugated with FITC, PE, APC, PerCp-Cy5.5, PE-Cy7, APC-Alexa750, Pacific blue, 
605eFluor or 650 eFluor (nano-crystals), respectively. Stained samples were run in a LSR Fortessa.
Statistics. Log-transformed means were compared between NHL HIV+ individuals and HIV+ controls 
using linear mixed models with a random effect for each pair examining each visit (>4 years and 1–4 years 
prior to NHL diagnosis) independently and also combined. When visits were combined in the same analysis, we 
evaluated the change in values across visits via an interaction term comprising an additional random effect for 
each individual to account for multiple observations per individual. We also compared log-transformed means 
between HIV+ controls and HIV-negative controls using linear regression models controlling for age. P-values 
were obtained from a t-test for the difference in corresponding means. When appropriate, least-square means 
Figure 3. Levels of CD19+CD24++CD38++ B cells were higher preceding DLCL than BL. Multicolor flow 
cytometry was performed in prospectively collected PBMC from DLBCL and BL 1–4 years prior to AIDS-
NHL diagnosis. Absolute numbers of CD19+CD24++CD38++ cells (cells/mm3) were measured. p-values were 
calculated using either an F-test for the difference in log means in a linear mixed model, respectively.
Gated on B 
CD19+PD-L1+
CD38 CD10 CD10 CD38
CD10CD38
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24
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1
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D
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20 14
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313
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11 13
1
2078
111
7523
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D
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Figure 4. CD19+PD-L1+ cells are a subpopulation within Bregs in peripheral blood precceding AIDS-NHL 
diagnosis. Detection of levels of Breg cells (CD19+CD24++CD38++) and CD19+PD-L1+ cells by multicolor flow 
cytometry from a representative AIDS-NHL case (1–4 years before diagnosis) and its matched HIV+ control.
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are presented. Analyses were done using the R statistical language package. p-values were also calculated using a 
Wilcoxon test.
B-cell exposure to HIV. B cells were isolated from fresh PBMC, obtained from HIV uninfected donors, 
by negative selection using the RosetteSep Human B Cell Enrichment kit (Stem Cell Technologies). B cells were 
exposed to X4-HIV strain (NL4–3) and/or an R5-HIV strain (JR-CSF) virions, containing or not containing 
CD40L, or T147N (non-functional CD40 mutant), at a concentration of 100 ng p24 per 1 × 106 B cells, or to 
anti-CD40 agonistic antibody (1 μg/ml) as a positive control (Biolegend), incubated for 2 hours, then plated at a 
concentration of 0.5 × 106 cells per ml, left at 37 °C for 3 days23, and stained as described above23. Supernatants 
of these cultures were assessed using Luminex-based high-sensitivity multiplexed immunometric assays (R&D 
Systems) to determine human cytokine levels. This assay can simultaneously measure levels of the following 
human cytokines: GM-CSF, IFNγ, IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL2 (p70), IL13 and TNFα23.
Ethics statement. This study involved the use of samples obtained from human subjects. Multicenter AIDS 
Cohort Study (MACS) at UCLA, which provided specimens and data obtained from human subjects, with per-
sonal identifying information removed, was approved by the Institutional Review Board (IRB) of the UCLAof the 
UCLA Human Research Protection Program (HRPP). All participants in the MACS provided written informed 
consent. The current study was determined by the UCLA IRB to be exempt from IRB review, as the information 
was provided in such a manner that subjects cannot be identified, directly or through identifiers linked to the 
subjects
Figure 5. CD40L+ HIV induces PD-L1 expression on B cells, as well as IL10 secretion. Isolated B cells were 
exposed to mock supernatants, anti-CD40 (positive control) CD40L+ HIV and T147N-HIV (CD40L mutant-
HIV) for 2 hours and then cultured at 37 °C for 3 days. (A) flow cytometry for PD-L1 was performed on 
cultured B cells and % of PD-L1+ B cells are shown, (B) IL10 levels in supernatants of cultured cells, measured 
using Luminex multiplexed assays. p-values were calculated using a Wilcoxon test.
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Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on rea-
sonable request. Methods were performed in accordance to the relevant guidelines and regulation.
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